HC Wainwright & Co. Maintains Buy on HOOKIPA Pharma, Lowers Price Target to $6.5
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Arthur He maintains a 'Buy' rating on HOOKIPA Pharma (NASDAQ:HOOK) but lowers the price target from $8 to $6.5.
August 11, 2023 | 10:47 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a 'Buy' rating on HOOKIPA Pharma but lowers the price target from $8 to $6.5.
The news is directly related to HOOKIPA Pharma and is likely to influence investor sentiment. While the 'Buy' rating is maintained, the lowered price target may indicate a potential downside, leading to mixed reactions in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100